X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (362) 362
index medicus (360) 360
hematology (311) 311
jak2v617f (289) 289
essential thrombocythemia (275) 275
janus kinase 2 - genetics (273) 273
polycythemia-vera (265) 265
mutation (241) 241
jak2v617f mutation (207) 207
female (194) 194
male (187) 187
middle aged (171) 171
myeloproliferative neoplasms (171) 171
oncology (169) 169
aged (150) 150
myelofibrosis (145) 145
jak2 (140) 140
adult (138) 138
tyrosine kinase jak2 (121) 121
myeloproliferative disorders (118) 118
polycythemia vera (115) 115
myeloproliferative disorders - genetics (114) 114
genetic aspects (104) 104
aged, 80 and over (93) 93
thrombosis (92) 92
jak2 v617f mutation (88) 88
disorders (84) 84
polycythemia vera - genetics (84) 84
primary myelofibrosis (76) 76
diagnosis (74) 74
risk factors (74) 74
thrombocythemia, essential - genetics (74) 74
myeloid metaplasia (69) 69
alleles (62) 62
tumors (62) 62
leukemia (61) 61
primary myelofibrosis - genetics (57) 57
hemic and lymphatic diseases (56) 56
research (56) 56
analysis (55) 55
medicine & public health (55) 55
animals (53) 53
myeloproliferative neoplasm (53) 53
gene mutations (52) 52
polycythemia (52) 52
adolescent (51) 51
chronic myeloproliferative disorders (50) 50
jak2v617f allele burden (49) 49
janus kinase 2 (48) 48
expression (47) 47
young adult (46) 46
care and treatment (44) 44
allele burden (43) 43
janus kinase 2 - metabolism (43) 43
activating mutation (42) 42
mutation, missense (41) 41
prognosis (41) 41
risk (41) 41
janus kinase 2 - antagonists & inhibitors (40) 40
disease (39) 39
jak2 mutation (39) 39
amino acid substitution (38) 38
myeloproliferative disorders - pathology (38) 38
peripheral vascular disease (38) 38
phenotype (38) 38
prevalence (38) 38
myeloproliferative disorders - diagnosis (37) 37
v617f mutation (37) 37
mice (36) 36
treatment outcome (36) 36
budd-chiari-syndrome (34) 34
jak2 v617f (34) 34
mutation - genetics (34) 34
venous thrombosis (34) 34
myeloproliferative disorders - drug therapy (33) 33
article (32) 32
cancer (32) 32
receptors, thrombopoietin - genetics (31) 31
abridged index medicus (30) 30
health aspects (30) 30
hematology, oncology and palliative medicine (30) 30
neoplasms (30) 30
polymerase chain reaction (30) 30
risk-factors (30) 30
venous thrombosis - genetics (30) 30
gene frequency (29) 29
hydroxyurea (28) 28
thromboembolism (28) 28
pathology (27) 27
polycythemia vera - pathology (27) 27
blood clot (26) 26
genetic predisposition to disease (26) 26
mpl (26) 26
survival (26) 26
myeloproliferative disorders - enzymology (25) 25
case-control studies (24) 24
chronic myeloid-leukemia (24) 24
polycythemia vera - drug therapy (24) 24
retrospective studies (24) 24
thrombocythemia (24) 24
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (545) 545
Russian (9) 9
Spanish (7) 7
German (6) 6
French (4) 4
Japanese (3) 3
Chinese (2) 2
Turkish (2) 2
Czech (1) 1
Hungarian (1) 1
Italian (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Investigation, ISSN 0021-9738, 02/2018, Volume 128, Issue 2, pp. 789 - 804
Journal Article
BLOOD, ISSN 0006-4971, 04/2019, Volume 133, Issue 15, pp. 1677 - 1690
Over 80% of patients with myeloproliferative neoplasms (MPNs) harbor the acquired somatic JAK2(V617F) mutation. JAK inhibition is not curative and fails to... 
PROGENITOR CELLS | JAK2V617F EXPRESSION | POLYCYTHEMIA-VERA | MYELOPROLIFERATIVE NEOPLASM | DEPENDENT KINASE 6 | JAK2 V617F MUTATION | PROLIFERATION | MYELOID MALIGNANCIES | CELL-CYCLE PROGRESSION | HEMATOLOGY | HEMATOPOIETIC STEM
Journal Article
British Journal of Haematology, ISSN 0007-1048, 11/2008, Volume 143, Issue 3, pp. 307 - 320
Summary Since the discovery of the JAK2V617F mutation, the clinical and pathological consequences of this acquired defect have been extensively investigated to... 
splanchnic vein thrombosis | thrombosis | polycythaemia rubra vera | JAK2V617F | essential thrombocythaemia | Polycythaemia rubra vera | Essential thrombocythaemia | Splanchnic vein thrombosis | JAK2 | Thrombosis
Journal Article
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 06/2012, Volume 10, Issue 6, pp. 998 - 1003
Journal Article
Journal Article
BLOOD, ISSN 0006-4971, 02/2018, Volume 131, Issue 6, pp. 649 - 661
Somatic mutations in the endoplasmic reticulum chaperone calreticulin (CALR) are detected in approximately 40% of patients with essential thrombocythemia (ET)... 
JAK2V617F EXPRESSION | TERT PROMOTER MUTATIONS | POLYCYTHEMIA-VERA | ACTIVATING MUTATION | MYELOPROLIFERATIVE NEOPLASMS | IN MOUSE MODEL | JAK2 | HEMATOLOGY | MYELOID METAPLASIA | HEMATOPOIETIC STEM | THROMBOPOIETIN RECEPTOR
Journal Article
THROMBOSIS AND HAEMOSTASIS, ISSN 0340-6245, 09/2018, Volume 118, Issue 9, pp. 1586 - 1599
Journal Article